Description: Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Home Page: www.cybin.com
100 King Street West
Toronto,
ON
M5X 1C9
Canada
Phone:
908 764 8385
Officers
| Name | Title |
|---|---|
| Mr. Eric So L.L.B., LLB | Co-Founder, Pres & Exec. Chairman |
| Mr. Douglas L. Drysdale | Chief Exec. Officer |
| Mr. Paul Glavine | Co-Founder, Chief Growth Officer & Director |
| Mr. John Kanakis | Co-Founder |
| Mr. Greg Cavers | Chief Financial Officer |
| Mr. Aaron Bartlone | Chief Operating Officer |
| Dr. Alex L. Nivorozhkin Ph.D. | Chief Scientific Officer |
| Ms. Leah Gibson | VP of Investor Relations & Strategic Communications |
| Ms. Lori Challenger | Chief Compliance, Ethics & Admin. Officer |
| Mr. Gabriel Fahel | Chief Legal Officer & Corp. Sec. |
Exchange: NEO
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0858 |
| Price-to-Sales TTM: | 277.808 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 50 |